Matches in Wikidata for { <http://www.wikidata.org/entity/Q67133257> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q67133257 description "clinical trial" @default.
- Q67133257 description "ensayu clínicu" @default.
- Q67133257 description "klinisch onderzoek" @default.
- Q67133257 description "клінічне випробування" @default.
- Q67133257 name "Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab" @default.
- Q67133257 name "Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab" @default.
- Q67133257 type Item @default.
- Q67133257 label "Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab" @default.
- Q67133257 label "Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab" @default.
- Q67133257 prefLabel "Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab" @default.
- Q67133257 prefLabel "Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab" @default.
- Q67133257 P1050 Q67133257-3F689F82-BE6C-49F0-9DBF-EBAFCB2A7774 @default.
- Q67133257 P1132 Q67133257-0A2365C6-AFA4-4FAB-84EB-F5EC8E6620B1 @default.
- Q67133257 P1476 Q67133257-BBB1971B-07ED-4E05-9958-886532A5A457 @default.
- Q67133257 P17 Q67133257-5DD1A8B2-C394-40D4-83BF-9828CDFBF03A @default.
- Q67133257 P17 Q67133257-EFF6C962-1D1D-428D-8755-3E485B7654EC @default.
- Q67133257 P2899 Q67133257-B326B96C-7F3E-4374-8B29-89A3BF602F42 @default.
- Q67133257 P3098 Q67133257-B43556A5-1BF1-4641-9ADE-06CF802E17CE @default.
- Q67133257 P31 Q67133257-A38A149B-BAE9-4D93-B0CF-0037C4C74A5B @default.
- Q67133257 P4844 Q67133257-FD584F13-2E31-4AB3-A30E-A46FF69CE3DD @default.
- Q67133257 P580 Q67133257-04C49A53-8C22-464C-9B00-D3A5A70A2770 @default.
- Q67133257 P582 Q67133257-F0738C9B-0DB4-41E0-8D1A-FE8FC5A41519 @default.
- Q67133257 P6099 Q67133257-61EB3B59-1901-4D4E-9471-81D6D3F8F230 @default.
- Q67133257 P6099 Q67133257-9E010419-563C-43C3-AB85-FDEBE37BD775 @default.
- Q67133257 P8363 Q67133257-8CC84579-91F4-4D2C-8A66-F62672C50F3C @default.
- Q67133257 P921 Q67133257-2DA1F7C7-CD85-4769-BEFC-A6514814F202 @default.
- Q67133257 P921 Q67133257-926E1DB0-3172-4917-8B57-BB8E1E25DC03 @default.
- Q67133257 P1050 Q1365309 @default.
- Q67133257 P1132 "+40" @default.
- Q67133257 P1476 "Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma Followed by a Phase 2 Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab and Phase 1 Dose-Escalation Study of Enterally-administered Marizomib With Bevacizumab" @default.
- Q67133257 P17 Q16 @default.
- Q67133257 P17 Q30 @default.
- Q67133257 P2899 "+18" @default.
- Q67133257 P3098 "NCT02330562" @default.
- Q67133257 P31 Q30612 @default.
- Q67133257 P4844 Q413299 @default.
- Q67133257 P580 "2015-04-15T00:00:00Z" @default.
- Q67133257 P582 "2020-02-18T00:00:00Z" @default.
- Q67133257 P6099 Q42824440 @default.
- Q67133257 P6099 Q5452194 @default.
- Q67133257 P8363 Q78089383 @default.
- Q67133257 P921 Q1365309 @default.
- Q67133257 P921 Q7404722 @default.